The Multiple Myeloma Research Foundation is hoping that an open-access research portal containing detailed longitudinal clinical and genomic data from multiple myeloma patients will spur collaborative research that advances much needed molecularly-targeted treatments.
While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.
NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced the signing of a collaborative agreement with Bristol-Myers Squibb for the use of Adaptive's technology to discover immunological biomarkers in cancer.
Qiagen said this week that GE Healthcare subsidiary Clarient will offer Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Opko Health said this week that it has expanded its collaboration with drugmaker Bristol-Myers Squibb to use its protein biomarker discovery platform to identify markers predictive of patient response to several BMS therapeutics.
NEW YORK (GenomeWeb News) – Opko Health said today that it has expanded a collaboration with Bristol-Myers Squibb to include biomarker discovery for pharmacogenomic tests for use in treating Alzheimer's disease.